Shield Therapeutics Advances ACCRUFeR® Clinical Trials in Japan for PAH

Shield Therapeutics ( (GB:STX) ) has provided an announcement.

Shield Therapeutics announced the initiation of a Phase II clinical trial in Japan for ACCRUFeR® (ferric maltol) as a treatment for Pulmonary Arterial Hypertension (PAH). This trial, conducted by its partner MEDLEAP Pharma, aims to support a Phase III trial and potential regulatory submissions by 2028. The development is significant as it addresses the challenges of long-term iron supplementation in PAH patients, potentially positioning ACCRUFeR® as a core treatment in this field.

The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Spark’s Take on GB:STX Stock

According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.

The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.

To see Spark’s full report on GB:STX stock, click here.

More about Shield Therapeutics

Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company that focuses on delivering innovative treatments for iron deficiency, with or without anemia. Its primary product, ACCRUFeR®/FeRACCRU® (ferric maltol), is a novel oral therapy for iron deficiency and is marketed in various regions including the U.S., Europe, and Asia through strategic partnerships.

Average Trading Volume: 3,929,778

Technical Sentiment Signal: Buy

Current Market Cap: £72.73M

For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.